Luis Pinheiro
Signal Management Lead
European Medicines Agency
Luis Pinheiro is a Signal Management Lead at the European Medicines Agency (EMA), where he is responsible for monitoring the safety of a portfolio of biopharmaceuticals and oncological products. He also provides pharmacoepidemiology and data science expertise in drug safety data analysis and coordinates the data analysis support to safety referrals within the Signal and Incident Management Service.
Prior to joining the EMA, he was the Head of the Signal Detection Unit (ad interim) at Infarmed, the Portuguese Regulatory Authority and Portuguese representative at the Pharmacovigilance Working Party at EMA. Before that, he worked in the Faculty of Pharmacy, University of Lisbon for eight years.
Luis received his Master’s in Epidemiology from the Faculty of Medicine, New University of Lisbon and is currently pursuing a PhD with Dr Peter Rijnbeek’s group at Erasmus MC.
Slattery, J, D Morales, L Pinheiro, and X Kurz (2018). Cohort study of psychiatric adverse events following exposure to
Levonorgestrel-containing intrauterine devices in UK general practice. Drug safety 41(10), 951–958.
Morales, DR, J Slattery, X Kurz, L Pinheiro, and K Hedenmalm (2017). Clinical Indications for Fluoroquinolones in Routine
Care. In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. Vol. 26. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, pp.595–
596.
Morales, DR, J Slattery, L Pinheiro, X Kurz, and K Hedenmalm (2018). Indications for systemic fluoroquinolone therapy in
Europe and prevalence of primary-care prescribing in France, Germany and the UK: descriptive population-based study.
Clinical drug investigation 38(10), 927–933.
Morales, DR, J Slattery, A Pacurariu, L Pinheiro, and X Kurz (2018). Association between systemic fluoroquinolone exposure
and peripheral neuropathy: Population-based nested case-control study. In: PHARMACOEPIDEMIOLOGY AND DRUG
SAFETY. Vol. 27. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, pp.337–338.
Slattery, J, D Morales, L Pinheiro, and X Kurz (2018). Investigation of psychiatric adverse events following exposure to
levonorgestrel containing IUDs. In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. Vol. 27. WILEY 111 RIVER ST, HOBOKEN
07030-5774, NJ USA, pp.217–217.
Morales, DR, J Slattery, A Pacurariu, L Pinheiro, P McGettigan, and X Kurz (2019). Relative and Absolute Risk of Tendon
Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–
Control Study. Clinical drug investigation 39(2), 205–213.
Morales, DR, J Slattery, A Pacurariu, L Pinheiro, P McGettigan, and X Kurz (2019). Correction to: Relative and Absolute Risk
of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based
Nested Case-Control Study. Clin Drug Investig.
Morales, D, A Pacurariu, J Slattery, L Pinheiro, P McGettigan, and X Kurz (2019). Association between peripheral neuropathy
and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy. JAMA neurology.
